Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9032911 | 0.82 | HIF1A (0.54) | HIF1AEPAS1 | |
| SCHEMBL5868243 | 0.82 | HIF1A (0.54) | HIF1AEPAS1 | |
| SCHEMBL30523641 | 0.81 | HIF1A (0.53) | HIF1AEPAS1 | |
| SCHEMBL507142 | 0.81 | HIF1A (0.53) | HIF1AEPAS1 | |
| SCHEMBL9032078 | 0.81 | HIF1A (0.53) | HIF1AEPAS1 | |
| Eulatachromene SCHEMBL9033640 | 0.81 | HIF1A (0.53) | HIF1AEPAS1 | |
| SCHEMBL2565400 | 0.79 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL2564310 | 0.78 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL14930293 | 0.78 | HIF1A (0.61) | HIF1AEPAS1 | |
| SCHEMBL2560364 | 0.77 | HIF1A (1.00) | HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062072-B2 | Inhibitors of HIF and angiogenesis | EMORY UNIVERSITY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885EPAS1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.